5GINC - Exploration of physiological reactions during controlled exposure to a 5G signal in the study of electrohypersensitivity

Last updated on 7-2-2024 by Maryse Ledent
Project duration:
January 1, 2024
December 31, 2024

In short

The 5GINC project seeks to improve knowledge of the ElectroHyperSensitivity (EHS) syndrome in the context of exposure to a 5G signal. EHS involves individuals attributing nonspecific symptoms to electromagnetic field (EMF) exposure, in the absence of other underlying pathology to explain these symptoms. In the previous projects ExpoComm and ENVI-EHS, volunteers were exposed to different EMF sources (2G-4G, WiFi, etc.). The results did not reveal links between exposure perception and the ON / OFF status of the exposure system. In 5GINC, we study the link between exposure to EMF (a 5G signal) and symptoms, based on objective measurements of skin reactions in the exposed area, and we study mutations in a gene that could lead to greater sensitivity to environmental agents.

Project description

The mobile communications network using 5G technology is currently being rolled out worldwide. This network is based on two main frequency ranges: the lower frequencies between 0.7 and 3.6 GHz (FR1 bands), which are close to the frequencies currently used in 2G-4G technologies, and the higher frequencies above 24,25 GHz (FR2 bands). FR1 frequencies are currently being deployed in Europe, including in Belgium. On the other hand, FR2 frequencies are not currently being deployed for the general public in Belgium. In order to improve knowledge of the potential health effects of large-scale deployment of these FR2 frequencies, work is underway to assess the potential risk (see also the Over5G citizen information platform).

In 5GINC, we expose people to a FR2 signal, of the type that could be deployed in Belgium in the next few years, at a non-thermal level. As the energy of these FR2 waves is absorbed in the superficial tissues of the skin, this project proposes to work in particular with people reporting EHS who describe symptoms at dermal level, such as redness, tingling or itching, when they are exposed to EMFs. We will compare the results with those of EHS sufferers who do not report such symptoms and non-EHS sufferers. 

We explore the possible link between the symptoms reported by EHS sufferers (particularly EHS sufferers complaining of dermal symptoms) and the 5G signal, and the effects of this signal on measurable parameters, with the aim of overcoming the limitations of people’s perceptions. We also investigate mutations in a gene predisposing European individuals to the early onset, severe and persistent development of atopic dermatitis and also to the form of asthma associated with atopic dermatitis.

Sciensano's project investigator(s):

Service(s) working on this project


Catherine Bouland
Jonathan White
Benjamin Vatovez

Associated Health Topics

QR code

QR code for this page URL